PURA - Puration Signs First CBD Beverage Distribution Agreement In Latin America
October 14 2019 - 2:47PM
InvestorsHub NewsWire
PURA – Puration Signs First CBD
Beverage Distribution Agreement In Latin America
Dallas, TX -- October 14, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced signing its first distribution agreement
for its EVERx CBD
Sports Water in Latin American. PURA has reported
over $1 million in CBD beverage sales in the first six months of
2019 after reporting approximately $1 million in sales for all of
2018. On top of its ongoing sales, PURA has signed a
new European
distribution agreement anticipated to generate $4 million
annually with a first shipment scheduled later this
month. In a recently published analyst report on PURA, the
analyst highlighted Latin America as an untapped opportunity for
CBD Beverages:
“An Untapped
Opportunity. Most
CBD analysts, companies, and investors are focused on the North
American markets, and to some degree, Europe. However, a burgeoning
untapped opportunity exists in the Caribbean markets. Countries
such as Trinidad are set to legalize CBD and cannabis for the first
time, creating an untapped, near-shore market
opportunity.”
Management plans to publish more details
on its strategy for Latin America later this week on Thursday,
October 17th.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024